Amended Statement of Ownership (sc 13g/a)
February 03 2021 - 3:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
TFF
Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.001
(Title of Class of Securities)
87241J104
(CUSIP Number)
December 31, 2020
(Date of Event which Requires Filing of this Statement)
Check the
appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule
13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
|
*
|
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
|
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONATINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL
NUMBER.
|
|
|
|
|
|
|
CUSIP No. 87241J104
|
|
13G
|
|
Page 2 of 4 Pages
|
|
|
|
|
|
|
|
|
|
1.
|
|
NAMES OF REPORTING PERSONS
Lung Therapeutics, Inc.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
46-1383209
|
|
2.
|
|
CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP (see instructions)
(a) ☐ (b) ☐
|
|
3.
|
|
SEC USE ONLY
|
|
4.
|
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
State of
Texas
|
|
|
|
|
|
|
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
|
5.
|
|
SOLE VOTING POWER
2,950,000
|
|
|
6.
|
|
SHARED VOTING POWER
0
|
|
|
7.
|
|
SOLE DISPOSITIVE POWER
2,950,000
|
|
|
8.
|
|
SHARED DISPOSITIVE POWER
0
|
|
|
|
|
|
|
|
|
|
9.
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,950,000
|
|
10.
|
|
CHECK IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
☐
|
|
11.
|
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (9)
13.3%
|
|
12.
|
|
TYPE OF REPORTING PERSON
(see instructions)
CO
|
|
|
|
|
|
|
|
CUSIP No. 87241J104
|
|
13G
|
|
Page 3 of 4 Pages
|
Item 1.
TFF Pharmaceuticals, Inc.
|
|
(b)
|
Address of Issuer’s Principal Executive Offices
|
|
|
|
2600 Via Fortuna, Suite 360
|
Austin, Texas 78746
Item 2.
|
|
(a)
|
Name of Person Filing
|
Lung Therapeutics, Inc.
|
|
(b)
|
Address of the Principal Office or, if none, residence
|
2600 Via Fortuna, Suite 360
Austin, Texas 78746
|
|
(c)
|
Citizenship State of Texas
|
|
|
(d)
|
Title of Class of Securities
|
Common Stock, par value $0.001
87241J104
Item 3. If this
statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable.
Item 4. Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
|
|
|
|
|
|
|
(a)
|
|
Amount beneficially owned: 2,950,000.
|
|
|
|
|
(b)
|
|
Percent of class: 13.3%.
|
|
|
|
|
(c)
|
|
Number of shares as to which the person has:
|
|
|
|
|
|
|
|
(i)
|
|
Sole power to vote or to direct the vote 2,950,000.
|
|
|
|
|
|
|
|
(ii)
|
|
Shared power to vote or to direct the vote 0.
|
|
|
|
|
|
|
|
(iii)
|
|
Sole power to dispose or to direct the disposition of 2,950,000.
|
|
|
|
|
|
|
|
(iv)
|
|
Shared power to dispose or to direct the disposition of 0.
|
|
|
|
|
|
|
|
CUSIP No. 87241J104
|
|
13G
|
|
Page 4 of 4 Pages
|
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five
percent of the class of securities, check the following ☐.
Item 6. Ownership of More than Five Percent on Behalf of Another
Person.
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Not Applicable
Item 8. Identification and
Classification of Members of the Group.
Not Applicable
Item 9. Notice of Dissolution of Group.
Not
Applicable
Item 10. Certification.
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
|
|
February 3, 2021
Date
|
|
|
|
/s/ Brian Windsor
Signature
|
|
|
|
Brian Windsor, President and CEO
Name/Title
|
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Mar 2024 to Apr 2024
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Apr 2023 to Apr 2024
